What You Should Know:
– Leo Cancer Care, a pioneer in radiotherapy treatment devices, has successfully raised $40M in funding round led by Catalio Capital Management.
– The investment, which also saw participation from new and existing investors, will accelerate the commercialization of Leo Cancer Care’s next-generation upright radiotherapy system. As part of the funding, Dr. Nicholas von Guionneau of Catalio has also joined Leo Cancer Care’s board as an Observer.
Marie: Upright Radiotherapy System
Leo Cancer Care’s first product, Marie®, is an upright patient positioning system and CT scanner designed for proton therapy. Named after physicist Marie Curie, the system replaces gantry rotation with patient rotation, which in turn reduces the size, cost, and complexity of proton therapy. This makes these advanced treatments more patient-friendly and globally accessible.
The Marie® system recently received510(k) clearance from the U.S. Food and Drug Administration (FDA). The technology has already been installed at multiple leading cancer centers in the U.S., with the first patient treatments anticipated later in 2025. According to Stephen Towe, Co-Founder and CEO of Leo Cancer Care, this investment highlights the growing recognition of upright radiotherapy’s potential to improve patient experiences and expand access to advanced treatments worldwide.
